Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole in adolescent schizophrenia
NCT03238326Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Aug 2017
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of brexpiprazole orally disintegrating tablet in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Aug 2017; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03238326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03238326.